Rankings
▼
Calendar
PCRX Q1 2025 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena
PCRX
Pacira BioSciences, Inc.
$971M
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$169M
+1.1% YoY
Gross Profit
$135M
79.7% margin
Operating Income
$2M
1.2% margin
Net Income
$5M
2.8% margin
EPS (Diluted)
$0.10
QoQ Revenue Growth
-9.8%
Cash Flow
Operating Cash Flow
$35M
Free Cash Flow
$27M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$788M
Stockholders' Equity
$799M
Cash & Equivalents
$284M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$169M
$167M
+1.1%
Gross Profit
$135M
$120M
+12.5%
Operating Income
$2M
$13M
-84.9%
Net Income
$5M
$9M
-46.4%
Revenue Segments
Product
$168M
51%
EXPAREL
$137M
41%
ZILRETTA
$23M
7%
Bupivacaine Liposome Injectable Suspension
$3M
1%
← FY 2025
All Quarters
Q2 2025 →